Cited by 615Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Open access

Orban, Tihamer, Bundy, Brian, Becker, Dorothy J, DiMeglio, Linda A, Gitelman, Stephen E, Goland, Robin, Gottlieb, Peter A, Greenbaum, Carla J, Marks, Jennifer B, Monzavi, Roshanak, Moran, Antoinette, Raskin, Philip, Rodriguez, Henry, Russell, William E, Schatz, Desmond, Wherrett, Diane, Wilson, Darrell M, Krischer, Jeffrey P, Skyler, Jay S·2011·The Lancet

DOI 10.1016/s0140-6736(11)60886-6PMC PMC3462593

Open this paper in CoChat — free account

Abstract

Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes. Methods In this multicentre, double-blind, randomised controlled trial, patients aged 6-45 years recently diagnosed with type 1 diabetes were randomly assigned (2:1) to receive abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years. Computer-generated permuted block randomisation was used, with a block size of 3 and stratified by participating site. Neither patients nor research personnel were aware of treatment assignments. The primary outcome was baseline-adjusted geometric mean 2-h area-under-the-curve (AUC) serum C-peptide concentration after a mixed-meal tolerance test at 2 years' follow-up. Analysis was by intention to treat for all patients for whom data were available. This trial is registered at ClinicalTrials.gov, NCT00505375. Findings 112 patients were assigned to treatment groups (77 abatacept, 35 placebo). Adjusted C-peptide AUC was 59% (95% CI 6·1-112) higher at 2 years with abatacept (n=73, 0·378 nmol/L) than with placebo (n=30, 0·238 nmol/L; p=0·0029). The difference between groups was present throughout the trial, with an estimated 9·6 months' delay (95% CI 3·47-15·6) in C-peptide reduction with abatacept. There were few infusion-related adverse events (36 reactions occurred in 17 [22%] patients on abatacept and 11 reactions in six [17%] on placebo). There was no increase in infections (32 [42%] patients on abatacept vs 15 [43%] on placebo) or neutropenia (seven [9%] vs five [14%]). Interpretation Co-stimulation modulation with abatacept slowed reduction in β-cell function over 2 years. The beneficial effect suggests that T-cell activation still occurs around the time of clinical diagnosis of type 1 diabetes. Yet, despite continued administration of abatacept over 24 months, the decrease in β-cell function with abatacept was parallel to that with placebo after 6 months of treatment, causing us to speculate that T-cell activation lessens with time. Further observation will establish whether the beneficial effect continues after cessation of abatacept infusions. Funding US National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60886-6

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Categorical Data Analysis
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citation

Show all 31 references

Sorted by citations

Items 101–200 of 615

C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet
Bogun, M. M., Bundy, B. N., Goland, R. S., & Greenbaum, C. J. (2020) · Diabetes Care · doi:10.2337/dc19-2288 · Cited by 72
Self-citation
Autoimmunity and Cancer—Two Sides of the Same Coin
Sakowska, J., Arcimowicz, Ł., Jankowiak, M., Papak, I., Markiewicz, A., Dziubek, K., Kurkowiak, M., Kote, S., Kaźmierczak-Siedlecka, K., Połom, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.793234 · Cited by 80
Anti-cytokine therapies in T1D: Concepts and strategies
Nepom, G. T., Ehlers, M. R., & Mandrup-Poulsen, T. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.003 · Cited by 72
CTLA4-Ig Restores Rejection of MHC Class-II Mismatched Allografts by Disabling IL-2-Expanded Regulatory T Cells
Charbonnier, L., Vokaer, B., Lemaitre, P. H., Field, K. A., Léo, O., & Moine, A. L. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04184.x · Cited by 73
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes
Jacobsen, L. M., Bundy, B. N., Greco, M. N., Schatz, D., Atkinson, M. A., Brusko, T. M., Mathews, C. E., Herold, K. C., Gitelman, S. E., Krischer, J. P., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0305 · Cited by 71
Self-citation
Regulatory T cell therapy for type 1 diabetes: May the force be with you
Gitelman, S. E., & Bluestone, J. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.011 · Cited by 69
Self-citation
T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review
Gomez-Touriño, I. M., Arif, S., Eichmann, M., & Peakman, M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.012 · Cited by 73
The rise, fall, and resurgence of immunotherapy in type 1 diabetes
Nasr, M. B., D’Addio, F., Usuelli, V., Tezza, S., Abdi, R., & Fiorina, P. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.07.004 · Cited by 68
Endoplasmic reticulum stress in beta cells and autoimmune diabetes
Clark, A. L., & Urano, F. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.006 · Cited by 73
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases
Price, J. D., & Tarbell, K. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00288 · Cited by 73
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
Khoury, S. J., Rochon, J., Ding, L., Byron, M., Ryker, K., Tosta, P., Gao, W., Freedman, M. S., Arnold, D. L., Sayre, P. H., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516662727 · Cited by 66
Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune DiseasesPreprint
Bluestone, J. A., & Bour-Jordan, H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007542 · Cited by 67
Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2
Dwyer, C. J., Ward, N. C., Pugliese, A., & Malek, T. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0739-1 · Cited by 65
Harnessing the power of regulatory T‐cells to control autoimmune diabetes: overview and perspective
Yu, H., Paiva, R., & Flavell, R. A. (2017) · Immunology · doi:10.1111/imm.12867 · Cited by 66
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Taylor, P. N., Collins, K. S., Lam, A. P., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00267-x · Cited by 72
Self-citation
IL-2 therapy in type 1 diabetes: “Trials” and tribulations
Long, S. A., Buckner, J. H., & Greenbaum, C. J. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.005 · Cited by 63
Self-citation
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes
Linsley, P. S., Greenbaum, C. J., Rosasco, M. G., Presnell, S., Herold, K. C., & Dufort, M. J. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0032-1 · Cited by 62
Self-citation
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse
Jayasimhan, A., Mansour, K. P., & Slattery, R. M. (2013) · Clinical Science · doi:10.1042/cs20120627 · Cited by 63
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
Greenbaum, C. J., Serti, E., Lambert, K., Weiner, L. J., Kanaparthi, S., Lord, S. M., Gitelman, S. E., Wilson, D. M., Gaglia, J. L., Griffin, K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150074 · Cited by 62
Self-citation
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 59
Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial
Raz, I., Ziegler, A. G., Linn, T., Schernthaner, G., Bonńici, F., Distiller, L. A., Giordano, C. S. D. S., Giorgino, F., de Vries, L., Mauricio, D., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1391 · Cited by 57
Retracted
Tissue regulatory T cells
Lui, P. P., Cho, I., & Ali, N. (2020) · Immunology · doi:10.1111/imm.13208 · Cited by 61
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
Piemonti, L., Keymeulen, B., Gillard, P., Linn, T., Bosi, E., Rose, L., Pozzilli, P., Giorgino, F., Cossu, E., Daffonchio, L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14770 · Cited by 53
IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy
Kuo, H., Huang, C., Lin, T., & Lin, C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw397 · Cited by 55
Activation pathways that drive CD4 + T cells to break tolerance in autoimmune diseases*
Krovi, S. H., & Kuchroo, V. K. (2022) · Immunological Reviews · doi:10.1111/imr.13071 · Cited by 56
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Greenbaum, C. J., VanBuecken, D., & Lord, S. M. (2019) · Drugs · doi:10.1007/s40265-018-1035-y · Cited by 56
Self-citation
Cell type–specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes
Dufort, M. J., Greenbaum, C. J., Speake, C., & Linsley, P. S. (2019) · JCI Insight · doi:10.1172/jci.insight.125556 · Cited by 54
Self-citation
Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients
Gorus, F., Balti, E. V., Vermeulen, I., Demeester, S., Dalem, A. V., Costa, O. R., Dorchy, H., Tenoutasse, S., Mouraux, T., Block, C. E. M. D., et al. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04675.x · Cited by 50
The problems and promises of research into human immunology and autoimmune disease
Roep, B. O., Buckner, J. H., Sawcer, S. J., Toes, R. E. M., & Zipp, F. (2012) · Nature Medicine · doi:10.1038/nm.2626 · Cited by 52
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Cabrera, S. M., Rigby, M. R., & Mirmira, R. G. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833634 · Cited by 51
Advances in targeting co‐inhibitory and co‐stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 50
Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes
Ostrov, D. A., Alkanani, A. K., McDaniel, K. A., Case, S. R., Baschal, E. E., Pyle, L. L., Ellis, S., Pöllinger, B., Seidl, K. J., Shah, V. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97739 · Cited by 54
Self-citation
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Linsley, P. S., Greenbaum, C. J., Speake, C., Long, S. A., & Dufort, M. J. (2019) · JCI Insight · doi:10.1172/jci.insight.126136 · Cited by 51
Self-citation
Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes
Bagge, S. L., Fotheringham, A. K., Leung, S. S., & Forbes, J. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21654 · Cited by 54
The case for an autoimmune aetiology of type 1 diabetes
Mannering, S. I., Pathiraja, V., & Kay, T. W. H. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12699 · Cited by 51
Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype
Patel, S., Ma, C. S., Fourlanos, S., & Greenfield, J. R. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.001 · Cited by 49
Biomarkers of β-Cell Stress and Death in Type 1 Diabetes
Mirmira, R. G., Sims, E. K., Syed, F., & Evans‐Molina, C. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0783-x · Cited by 50
De‐ coding genetic risk variants in type 1 diabetes
Shapiro, M. R., Thirawatananond, P., Peters, L. D., Sharp, R. C., Ogundare, S. O., Posgai, A. L., Perry, D. J., & Brusko, T. M. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12438 · Cited by 47
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
Marchand, L., Disse, E., Dalle, S., Reffet, S., Vouillarmet, J., Fabien, N., Thivolet, C. H., & Cugnet‐Anceau, C. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01402-w · Cited by 48
Whole-genome CRISPR screening identifies genetic manipulations to reduce immune rejection of stem cell-derived islets
Sintov, E., Nikolskiy, I., Barrera, V., Hyoje-Ryu Kenty, J., Atkin, A. S., Gerace, D., Ho Sui, S. J., Boulanger, K., & Melton, D. A. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.08.002 · Cited by 45
What is the role of autoimmunity in type 1 diabetes? A clinical perspective
Donath, M. Y., Hess, C., & Palmer, E. (2014) · Diabetologia · doi:10.1007/s00125-013-3153-0 · Cited by 44
The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Beam, C. A., Boulware, D. C., Greenbaum, C. J., Rafkin, L. E., Cowie, C., Cuthbertson, D., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0011 · Cited by 44
Self-citation
Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes
Greenbaum, C. J., Schatz, D., Haller, M. J., & Sanda, S. (2012) · Diabetes · doi:10.2337/db11-1452 · Cited by 46
Self-citation
Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes
Gootjes, C., Zwaginga, J. J., Roep, B. O., & Nikolić, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886736 · Cited by 44
The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?
Mallone, R., Halliez, C., Rui, J., & Herold, K. C. (2022) · Diabetes · doi:10.2337/dbi21-0036 · Cited by 41
Tolerogenic dendritic cells impede priming of naïve CD 8+ T cells and deplete memory CD 8+ T cells
Kleijwegt, F. S., Jansen, D. T. S. L., Teeler, J., Joosten, A. M., Laban, S., Nikolić, T., & Roep, B. O. (2012) · European Journal of Immunology · doi:10.1002/eji.201242879 · Cited by 43
Trials in type 1 diabetes: Antigen-specific therapies
Coppieters, K. T., Harrison, L. C., & von Herrath, M. G. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.002 · Cited by 43
Residual C-peptide in type 1 diabetes: what do we really know?
VanBuecken, D., & Greenbaum, C. J. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12135 · Cited by 43
Self-citation
Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes
Rydén, A. K., Perdue, N., Pagni, P. P., Gibson, C. B., Ratliff, S. S., Kirk, R. K., Friesen, T. J., Haase, C., Coppieters, K. T., von Herrath, M. G., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.006 · Cited by 44
Combination immunotherapy for type 1 diabetes
Bone, R. N., & Evans-Molina, C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0878-z · Cited by 41
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus
Vanikar, A. V., Trivedi, H. L., & Thakkar, U. G. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.006 · Cited by 44
Immune Mechanisms and Pathways Targeted in Type 1 Diabetes
Jacobsen, L. M., Newby, B. N., Perry, D. J., Posgai, A. L., Haller, M. J., & Brusko, T. M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1066-5 · Cited by 42
Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes
Orabona, C., Mondanelli, G., Puccetti, P., & Grohmann, U. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.005 · Cited by 42
A Randomized Controlled Trial to Evaluate Inhibition of T-Cell Costimulation in Allergen-induced Airway Inflammation
Parulekar, A. D., Boomer, J. S., Patterson, B., Yin‐Declue, H., Deppong, C. M., Wilson, B. S., Jarjour, N. N., Castro, M., & Green, J. M. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1205oc · Cited by 42
New and future immunomodulatory therapy in type 1 diabetes
Tooley, J., Waldron-Lynch, F., & Herold, K. C. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.01.001 · Cited by 44
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances
Mukherjee, N., Lin, L., Contreras, C., & Templin, A. T. (2021) · Metabolites · doi:10.3390/metabo11110796 · Cited by 44
Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles
Esposito, L., Hunter, K. M. D., Clark, J., Rainbow, D. B., Stevens, H. E., Denesha, J., Duley, S., Dawson, S., Coleman, G., Nutland, S. L., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303389 · Cited by 40
Targeting Memory T Cells in Type 1 Diabetes
Ehlers, M. R., & Rigby, M. R. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0659-5 · Cited by 40
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review
Thakkar, S., Chopra, A., Nagendra, L., Kalra, S., & Bhattacharya, S. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.2.7 · Cited by 49
CD28 and ITK signals regulate autoreactive T cell trafficking
Jain, N., Miu, B., Jiang, J., McKinstry, K. K., Prince, A., Swain, S. L., Greiner, D. L., Thomas, C. J., Sanderson, M. J., Berg, L. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3393 · Cited by 39
Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
Szentpétery, Á., Heffernan, E. J., Gogarty, M., Mellerick, L., McCormack, J., Haroon, M., Elmamoun, M., Gallagher, P., Kelly, G., Fabre, A., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1364-3 · Cited by 39
T Cell Receptor Profiling in Type 1 Diabetes
Jacobsen, L. M., Posgai, A. L., Seay, H. R., Haller, M. J., & Brusko, T. M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0946-4 · Cited by 38
Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes
Kwiatkowski, A. J., Stewart, J. M., Cho, J. J., Avram, D., & Keselowsky, B. G. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000164 · Cited by 43
Screening and Prevention of Type 1 Diabetes: Where Are We?
Simmons, K. M., & Sims, E. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad328 · Cited by 41
Restoring Regulatory T Cells in Type 1 Diabetes
Spence, A. L., & Tang, Q. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0807-6 · Cited by 38
Targeting Cellular Calcium Homeostasis to Prevent Cytokine-Mediated Beta Cell Death
Clark, A. L., Kanekura, K., Lavagnino, Z., Spears, L. D., Abreu, D., Mahadevan, J., Yagi, T., Semenkovich, C. F., Piston, D. W., & Urano, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-05935-4 · Cited by 38
CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes
Rachid, O., Osman, A., Abdi, R., & Haik, Y. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1727885 · Cited by 38
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
Linsley, P. S., Greenbaum, C. J., & Nepom, G. T. (2021) · Diabetes · doi:10.2337/db20-1185 · Cited by 38
Self-citation
Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes
Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Cabrera, S. M., Engle, S., Kaldunski, M. L., Jia, S., Geoffrey, R., Simpson, P. M., Szabó, A., Speake, C., Greenbaum, C. J., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4708-x · Cited by 35
Self-citation
Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond
Christophersen, A. O., Risnes, L. F., Dahal‐Koirala, S., & Sollid, L. M. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.009 · Cited by 36
Engineering antigen-specific immunological tolerance
Kontos, S., Grimm, A. J., & Hubbell, J. A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.05.005 · Cited by 36
Evolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
Latres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35
Self-citation
Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus
Rachmiel, M., Strauss, P., Dror, N., Benzaquen, H., Horesh, O., Tov, N., Weintrob, N., Landau, Z., Ben‐Ami, M., Haim, A., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12283 · Cited by 35
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
Axelsson, S., Chéramy, M., Åkerman, L., Pihl, M., Ludvigsson, J., & Casas, R. (2013) · Diabetes Care · doi:10.2337/dc12-2251 · Cited by 35
Impact of Disease Heterogeneity on Treatment Efficacy of Immunotherapy in Type 1 Diabetes: Different Shades of Gray
Woittiez, N. J. C., & Roep, B. O. (2015) · Immunotherapy · doi:10.2217/imt.14.104 · Cited by 35
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
Li, L., Liu, S., & Yu, J. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820958329 · Cited by 37
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
Rathod, S. (2022) · Diabetology · doi:10.3390/diabetology3010007 · Cited by 33
A historical view from thirty eventful years of immunotherapy in autoimmune diabetes
Bach, J.-F., & Chatenoud, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.009 · Cited by 41
Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants
de Jong, V. M., Zaldumbide, A., van der Slik, A. R., Persengiev, S. P., Roep, B. O., & Koeleman, B. P. C. (2012) · Genes and Immunity · doi:10.1038/gene.2012.38 · Cited by 33
Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial
Waldron-Lynch, F., Kareclas, P., Kathryn, I., Walker, N. M., Mander, A., Wicker, L. S., Todd, J. A., & Bond, S. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005559 · Cited by 31
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Galligan, A., Xu, W., Fourlanos, S., Nankervis, A. J., Chiang, C. Y., Mant, A. M., Parente, P., Rischin, D., Krishnamurthy, B., Sandhu, S. K., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13762 · Cited by 33
Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
Kroger, C. J., Clark, M., Qi, K., & Tisch, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01891 · Cited by 35
CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation
Shapiro, M. R., Yeh, W.-I., Longfield, J. R., Gallagher, J., Infante, C. M., Wellford, S., Posgai, A. L., Atkinson, M. A., Campbell‐Thompson, M., Lieberman, S. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02180 · Cited by 33
From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes
den Hollander, N. H. M., & Roep, B. O. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.932086 · Cited by 33
Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice
Sarikonda, G., Sachithanantham, S., Manenkova, Y., Kupfer, T., Posgai, A. L., Wasserfall, C. H., Bernstein, P., Straub, L., Pagni, P. P., Schneider, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054712 · Cited by 35
Functional Characterization of Human T Cell Hyporesponsiveness Induced by CTLA4-Ig
Rochman, Y., Yukawa, M., Kartashov, A. V., & Barski, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122198 · Cited by 33
Mechanistic Evidence in Support of Alpha1-Antitrypsin as a Therapeutic Approach for Type 1 Diabetes
Freixo-Lima, G. S., Ventura, H. C., Medini, M., Bar, L. K., Strauss, P., & Lewis, E. C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814547096 · Cited by 33
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care
Greenbaum, C. J. (2021) · Diabetes · doi:10.2337/db20-1112 · Cited by 34
Self-citation
Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes
Khan, F. U., Khongorzul, P., Raki, A. A., Rajasekaran, A., Gris, D., & Amrani, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094885 · Cited by 32
Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition
Kim, D.-H., Lee, J.-C., Lee, M., Kim, K.-W., & Lee, M.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2723-x · Cited by 32
Variation in the CTLA4 3′UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes
de Jong, V. M., Zaldumbide, A., van der Slik, A. R., Laban, S., Koeleman, B. P. C., & Roep, B. O. (2015) · Genes and Immunity · doi:10.1038/gene.2015.51 · Cited by 32
Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?
Steck, A. K., Xu, P., Geyer, S. M., REDONDO, M. J., Antinozzi, P. A., Wentworth, J. M., Sosenko, J. M., Önengüt-Gümüşcü, S., Chen, W., Rich, S. S., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-4003 · Cited by 32
Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes
Rosenzwajg, M., Churlaud, G., Hartemann, A., & Klatzmann, D. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0553-6 · Cited by 31
Can Existing Drugs Approved for Other Indications Retard Renal Function Decline in Patients With Type 1 Diabetes and Nephropathy?
Doria, A., Niewczas, M. A., & Fiorina, P. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.07.006 · Cited by 31
Circulating Unmethylated Insulin DNA As a Biomarker of Human Beta Cell Death: A Multi-laboratory Assay Comparison
Speake, C., Ylescupidez, A., Neiman, D., Shemer, R., Gläser, B., Tersey, S. A., Usmani‐Brown, S., Clark, P. L., Wilhelm, J. J., Bellin, M. D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa008 · Cited by 30
Immunotherapy Strategies for the Prevention and Treatment of Distinct Stages of Type 1 Diabetes: An Overview
Rapini, N., Schiaffini, R., & Fierabracci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062103 · Cited by 31

Authors: Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., Moran, A., Raskin, P., Rodriguez, H., Russell, W. E., Schatz, D., Wherrett, D., Wilson, D. M., Krischer, J. P., & Skyler, J. S.
Affiliations: Joslin Diabetes Center (US)
University of South Florida (US)
University of Pittsburgh (US)
Indiana University School of Medicine (US)
University of California, San Francisco (US)
Columbia University (US)
Benaroya Research Institute (US)
University of Miami (US)
Children's Hospital Los Angeles (US)
University of Minnesota (US)
The University of Texas Southwestern Medical Center (US)
Vanderbilt University (US)
University of Florida (US)
University of Toronto (CA)
Stanford University (US)
Corresponding author: Skyler, Jay S
ORCID: Bundy, Brian
DiMeglio, Linda A
Gitelman, Stephen E
Gottlieb, Peter A
Greenbaum, Carla J
Marks, Jennifer B
Monzavi, Roshanak
Moran, Antoinette
Rodriguez, Henry
Russell, William E
Schatz, Desmond
Wherrett, Diane
Wilson, Darrell M
Krischer, Jeffrey P
Skyler, Jay S
Venue: The Lancet
Publisher: Elsevier BV
Published: 2011-07
Volume: 378
Issue: 9789
Pages: 412-419
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(11)60886-6
PMC: PMC3462593
OpenAlex: W2154694193
Cited by: 612
References: 31
Citations by year: 2026: 26 · 2025: 40 · 2024: 52 · 2023: 30 · 2022: 33 · 2021: 34 · 2020: 43 · 2019: 32 · 2018: 41 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 46 · 2013: 57 · 2012: 45
FWCI: 31.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Funders: Sanofi
University of Florida
University of Washington
MacroGenics
Novo Nordisk
National Institutes of Health (5ul1rr031986-02)
National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, U01DK061040, U01DK085461, U01DK085505, U01DK085499, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK085504, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, U01DK085509, U01 DK-061016)
U.S. National Library of Medicine (HHSN267200800019C)
National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: abatacept, type 1 diabetes, recent-onset type 1 diabetes, T cell costimulation, T cell-mediated autoimmunity, C-peptide, beta-cell function, immunomodulation, mixed meal tolerance test, infusion-related adverse events, infection, neutropenia, children and adolescents, disease progression, HLA-DR
MeSH terms: Abatacept, Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, T-Lymphocytes, Autoimmunity, Randomized Controlled Trials as Topic, Immunoconjugates, Insulin-Secreting Cells, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks